BMS-936559

high-affinity, fully human, PD-L1–specific, IgG4 (S228P) monoclonal antibody that inhibits the binding of programmed death-ligand 1(PD-L1) to programmed cell death protein 1(PD-1) and CD80

Also Known As:

Networked: 5 relevant articles (0 outcomes, 1 trials/studies)

Bio-Agent Context: Research Results

Experts

1.	Grasela, Dennis M: 2 articles (01/2019 - 01/2017)
2.	Angus, Derek C: 1 article (01/2019)
3.	Brakenridge, Scott: 1 article (01/2019)
4.	Catlett, Ian M: 1 article (01/2019)
5.	Colston, Elizabeth: 1 article (01/2019)
6.	Coopersmith, Craig M: 1 article (01/2019)
7.	Crouser, Elliott D: 1 article (01/2019)
8.	Girgis, Ihab G: 1 article (01/2019)
9.	Hotchkiss, Richard S: 1 article (01/2019)
10.	Martin, Greg S: 1 article (01/2019)

Related Diseases

1.	Pneumonia (Pneumonitis) 01/01/2013 - "Despite the lack of studies directly comparing these agents, toxicities from PD-1 inhibition seem milder than those of CTLA-4 inhibition, with distinct toxicities of pneumonitis infrequently observed with the BMS-936558 anti-PD-1 antibody, nivolumamb, and frequent mild infusion reactions reported with the BMS-936559 anti-PDL-1 antibody. "
2.	Sepsis (Septicemia) 01/01/2019 - "In this first clinical evaluation of programmed cell death protein-1/programmed cell death-ligand 1 pathway inhibition in sepsis, BMS-936559 was well tolerated, with no evidence of drug-induced hypercytokinemia or cytokine storm, and at higher doses, some indication of restored immune status over 28 days. "
3.	Prostatic Neoplasms (Prostate Cancer) 04/01/2013 - "This review discusses the preclinical rationale for PD-1 pathway inhibition in advanced renal cell carcinoma and prostate cancer, in addition to the clinical activity and toxicity of the anti-PD-L1 antibody BMS-936559, as well as anti-PD-1 antibodies MK-3475 and BMS-936558."
4.	Neoplasms (Cancer) 06/01/2015 - "Cytotoxic T lymphocyte antigen-4 (CTLA-4), and the immune checkpoint inhibitor mAbs ipilimumab and tremelimumab, represent the prototypes of this new growing class of agents called immunomodulating antibodies, while programmed death/ligand 1 (PD-1/PD-L1) also has garnered a significant interest as a new immune checkpoints to target in urothelial cancer, with the anti-PD-1/PD-L1 inhibitor mAbs nivolumab, MPDL-3280, and BMS-936559 as the first agents tested. "
5.	Renal Cell Carcinoma (Grawitz Tumor) 04/01/2013 - "This review discusses the preclinical rationale for PD-1 pathway inhibition in advanced renal cell carcinoma and prostate cancer, in addition to the clinical activity and toxicity of the anti-PD-L1 antibody BMS-936559, as well as anti-PD-1 antibodies MK-3475 and BMS-936558."

Related Drugs and Biologics

1.	Nivolumab
2.	Antibodies
3.	Programmed Cell Death 1 Receptor
4.	B7-H1 Antigen
5.	Ligands
6.	Immune Checkpoint Inhibitors
7.	Ipilimumab
8.	pembrolizumab
9.	tremelimumab